Quality Control– tag –
-
Serum-Free Media Drives Cell Culture Standardization, Ensuring Reproducibility and Safety Through Defined Composition and Reduced Batch Variability
Procell Germany Overview Comparing serum-containing and serum-free media in cell culture, the article highlights that serum-free media offer clearly defined compositions, minimal batch-to-batch variability, and improved experimental repr... -
Australia’s VVMF Sydney Facility Secures TGA GMP License for Gene and Cell Therapy Manufacturing, Bolstering Domestic CDMO Capacity
Contract Pharma USA Overview Australia's Viral Vector Manufacturing Facility (VVMF) has officially received a Therapeutic Goods Administration (TGA) GMP license for therapeutic product manufacturing at its Sydney site, effective Septembe... -
iPSC Therapies: Manufacturing Consistency Requires Preserving Cell Functionality Beyond Basic Properties, Integrating Cell Line Selection and Genetic Engineering
Pharma's Almanac USA Overview An article in Pharma's Almanac highlights that iPSC-derived cardiomyocyte products, even with similar identity and purity, can exhibit differing functional performance, emphasizing the critical need to chara... -
Automated iPSC Manufacturing Achieves Monoclonal Lines in Seven Weeks, Paving Way for Cost-Efficient Clinical Autologous Therapies
bioRxiv Unknown Overview A new study introduces a highly efficient, standardizable, and automatable workflow for generating monoclonal induced pluripotent stem cell (iPSC) lines from human skin biopsies, including comprehensive quality c... -
Huazhong University of Science and Technology Tongji Hospital Demonstrates In Vivo CAR-T Therapy, Achieving Cost Reduction and Immune Reset for Multiple Sclerosis
Chosunbiz South Korea Overview A research team at Huazhong University of Science and Technology Tongji Hospital has demonstrated in vivo CAR-T therapy for autoimmune diseases like multiple sclerosis, successfully reducing manufacturing a... -
Japan’s Stem Cell Therapy Landscape: High Costs and Strict MHLW Regulations Govern Regenerative Medicine Hubs
PlacidWay Japan Overview Leading stem cell therapy clinics in Japan, such as Cell Grand Clinic and Clinique Haru Osaka Umeda, offer regenerative medicine for conditions like joint disorders, musculoskeletal diseases, diabetes, and Parkin... -
Evonik Invests $108M in Vancouver GMP Facility, Significantly Expanding Lipid-Based Drug Delivery Manufacturing Capacity
Contract Pharma USA Overview Evonik has announced a significant investment of $108 million into its GMP formulation manufacturing facility in Vancouver, Canada, dedicated to lipid-based drug delivery. This substantial capital injection a... -
Retinal Diseases Emerge as Key Proving Ground for Next-Gen iPSC Regenerative Therapies, BioProcess International Reports
BioProcess International USA Overview BioProcess International reports that iPSC-derived regenerative therapies are increasingly seen as the primary proving ground for next-generation treatments in retinal diseases. iPSCs enable scalable... -
REPROCELL Accelerates Clinical-Grade iPSC Manufacturing Scale-Up with StemRNA™ Clinical Platform and AI-Driven StemEdit
REPROCELL Japan Overview REPROCELL is significantly accelerating the scale-up of clinical-grade induced pluripotent stem cell (iPSC) manufacturing by leveraging its proprietary StemRNA™ Clinical iPSC platform and AI-driven StemEdit gene-... -
KOLON Biotech Expands Comprehensive CDMO Services in Korea, Specializing in Cell, Gene, and Exosome Therapies
MTEC South Korea Overview KOLON Biotech in South Korea is bolstering its capabilities as a specialized Contract Development and Manufacturing Organization (CDMO) for advanced cell, gene, and exosome therapies. The company offers end-to-e...
